← FDA DRUG APPROVALS

FDA ANDA · ANDA202960

ATOVAQUONE

Sponsor: AMNEAL PHARMS

APPLICATION
ANDA202960
TYPE
ANDA
ORIGINAL APPROVAL
2014-03-18
LATEST ACTION
2019-09-20
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Prescription

Products

ATOVAQUONEPrescription
ATOVAQUONE 750MG/5ML · SUSPENSION · ORAL

Approval history

2019-09-20Labeling · Supplement 9 · standardAP
2019-09-20Labeling · Supplement 7 · standardAP
2018-12-21Labeling · Supplement 2 · standardAP
2018-12-21Labeling · Supplement 5 · standardAP
2014-03-18UNKNOWN · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →